Daratumumab under the skin with a new device
Part of Blood & lymphatic, Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new device called FreedomEDGE® that gives daratumumab under the skin instead of by an IV. It might make your monthly treatment faster and more comfortable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma or light chain amyloidosis.
- Your doctor has prescribed daratumumab to be given under the skin.
- You receive your daratumumab treatment at a day hospital.
- You are in the monthly injection period of your daratumumab treatment.
- Until now, your daratumumab has been given manually (not with a device).
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
This study looks at whether people with multiple myeloma can safely give themselves daratumumab injections at home, instead of going to the hospital each time. You'll get the same medicine, but learn to manage it yourself with support, and share your experience through questionnaires and an interview.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
Hear when a new Multiple Myeloma or Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.